Abstract

The numbers of cases of arboviral diseases have increased in tropical and subtropical regions while the coronavirus disease (COVID-19) pandemic overwhelms healthcare systems worldwide. The clinical manifestations of arboviral diseases, especially dengue fever, can be very similar to COVID-19, and misdiagnoses are still a reality. In the meantime, outcomes for patients and healthcare systems in situations of possible syndemic have not yet been clarified. We set out to conduct a systematic review to understand and summarize the evidence relating to clinical manifestations, disease severity and prognoses among patients coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and arboviruses. We conducted a rapid systematic review with meta-analysis, on prospective and retrospective cohorts, case-control studies and case series of patients with confirmed diagnoses of SARS-CoV-2 and arboviral infection. We followed the Cochrane Handbook recommendations. We searched EMBASE, MEDLINE, Cochrane Library, LILACS, Scopus and Web of Science to identify published, ongoing and unpublished studies. We planned to extract data and assess the risk of bias and the certainty of evidence of the studies included, using the Quality in Prognosis Studies tool and the Grading of Recommendations Assessment. We were able to retrieve 2,407 citations using the search strategy, but none of the studies fulfilled the inclusion criteria. The clinical presentations, disease severity and prognoses of patients coinfected with SARS-CoV-2 and arboviruses remain unclear. Further prospective studies are necessary in order to provide useful information for clinical decision-making processes. CRD42020183460.

Highlights

  • Since the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, the coronavirus disease (COVID-19) has spread worldwide

  • The data would be extracted through a Microsoft Excel file and would comprise information relating to study design and setting, demographic and clinical characteristics, time points used for the assessments, epidemiological characteristics, outcomes, numbers of participants, means, standard deviations, standard errors, medians, interquartile ranges, minimums, maximums, 95% confidence intervals (CI) and p-values, among other information

  • While extraordinary attention has been given to finding effective interventions for treating patients with COVID-19, this review highlights that no significant efforts have been made to look at situations of coinfection with SARS-CoV-2 and the arboviral diseases that are already endemic in tropical and subtropical regions, and present in some temperate regions.[6]

Read more

Summary

INTRODUCTION

Since the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, the coronavirus disease (COVID-19) has spread worldwide. Up to July 9, 2020, almost 12 million cases had been confirmed, with 545,481 deaths, in 213 countries and territories around the world, as reported to the World Health Organization (WHO).[1,2] Amidst this pandemic, the world still needs to deal with the burden of various other diseases that present overlapping occurrences. There still is a lack of information on the impact of coinfection with these diseases on patients’ clinical manifestations, the potential for severe disease and the prognosis This knowledge is of vital importance for enabling adequate medical approaches towards these types of cases and, for applying the most appropriate treatment

METHODS
DISCUSSION
CONCLUSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.